Skip to main content
Clinical Trials/NCT00868803
NCT00868803
Active, not recruiting
Not Applicable

Identification of Aberant Gene Expression in Human Prostatic Carcinoma

Lahey Clinic1 site in 1 country5,000 target enrollmentApril 1995
ConditionsProstate Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prostate Cancer
Sponsor
Lahey Clinic
Enrollment
5000
Locations
1
Status
Active, not recruiting
Last Updated
11 months ago

Overview

Brief Summary

The goal of the study is to gain a better understanding of the molecular changes responsible for causing prostate cancer and that examination of tissue and blood samples will help in the development of improved screening and therapeutic approaches.

Detailed Description

The goal of this study is to identify novel genetic elements that are aberantly expressed throughout prostatic neoplastic progression. The approaches proposed exploit the known familial arm of prostatic cancer, using established molecular genetic approaches, and extend these studies to sporadic prostatic cancer using a novel technique of differential display. Application of the latter technique to colon cancer in the American population establishes this tumor type as a high priority for scientific investigation and this study is part of an initiative to address this problem. Presently the studies in the field of prostate are under-represented. The collection of tissue samples from patients diagnosed with prostate cancer. Patients will also provide a blood sample at the time of their surgery and potentially post-op from 6 mos to 5 years. Samples will also be obtained from patients who's biopsy turns out to be non-prostate cancer. These samples will be obtained shortly following the biopsy out to 6 months after the biopsy.

Registry
clinicaltrials.gov
Start Date
April 1995
End Date
April 2030
Last Updated
11 months ago
Study Type
Observational
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Linda Topjian

study coordinator

Lahey Clinic

Eligibility Criteria

Inclusion Criteria

  • Diagnosed prostate cancer undergoing prostatectomy
  • Suspicion of prostate cancer undergoing biopsy - negative biopsy
  • Health volunteer (control group) - blood sample for PSA

Exclusion Criteria

  • Patients not fitting the inclusion criteria

Outcomes

Primary Outcomes

Not specified

Study Sites (1)

Loading locations...

Similar Trials